Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Company Drug

J&J Submits Regulatory Filings for Darzalex Faspro and Subcutaneous Daratumumab

Fineline Cube Nov 11, 2024

Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of regulatory filings for its...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for Multiple Clinical Trials of Oncology Drugs

Fineline Cube Nov 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a Chinese pharmaceutical company, has announced that it...

Company Drug

Alphamab Oncology Presents JSKN033 Phase I/II Study Results at SITC 2024

Fineline Cube Nov 11, 2024

Alphamab Oncology (HKG: 9966), a China-based biopharmaceutical company, has announced the presentation of the latest...

Company Drug

Sino Biopharmaceutical Ltd Receives NMPA Approval for KRAS G12C Inhibitor Garsorasib

Fineline Cube Nov 11, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced that it...

Company Deals Drug

Daiichi Sankyo and Alteogen Sign $300 Million Deal to Develop Subcutaneous Enhertu

Fineline Cube Nov 9, 2024

Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has entered into a potentially $300...

Company Drug

Dizal Pharmaceutical Submits NDA to FDA for Sunvozertinib as NSCLC Therapy

Fineline Cube Nov 9, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a Chinese pharmaceutical company, has announced the submission of...

Company Deals

MGI Tech Co., Ltd Partners with Human Cell Atlas Consortium to Advance Cell Mapping

Fineline Cube Nov 8, 2024

China-based gene sequencing specialist, MGI Tech Co., Ltd, (SHA: 688114) has announced a commercial collaboration...

Company

AstraZeneca Confirms Executive Vice President Leon Wang’s Detention in China

Fineline Cube Nov 8, 2024

AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has provided an update to...

Company Deals

Jiangsu Kanion Pharmaceutical to Acquire Xintrum Pharmaceuticals for RMB 270 Million

Fineline Cube Nov 8, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a China-based pharmaceutical company, has announced its intention...

Company Drug

Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial

Fineline Cube Nov 8, 2024

Ascletis Pharma Inc. (HKG: 1672), a China-based pharmaceutical company, has announced positive results from a...

Company Deals

Nuwacell Biotechnologies Secures RMB150 Million in Series B Financing for iPSC Therapies

Fineline Cube Nov 8, 2024

Nuwacell Biotechnologies Co., Ltd., a specialist in induced pluripotent stem cell (iPSC) technology based in...

Company Deals

Shanghai Henlius Biotech Partners with SVAX to Boost MENAT Region’s Access to Biological Drugs

Fineline Cube Nov 8, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading Chinese biotech company, has entered into a...

Company Medical Device

Johnson & Johnson MedTech’s Varipulse Platform Receives FDA Approval for Atrial Fibrillation Treatment

Fineline Cube Nov 8, 2024

Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received marketing approval...

Company Drug

Sichuan Biokin Pharmaceutical Gets FDA Approval for Phase I Study of BL-M17D1 in Solid Tumors

Fineline Cube Nov 8, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Medical Device

Bayer AG Receives FDA 510(k) Clearance for MEDRAD Centargo CT Injection System

Fineline Cube Nov 8, 2024

Germany-based Bayer AG (ETR: BAYN) has announced that it has received 510(k) clearance from the...

Company Drug

Sichuan Huiyu Pharmaceutical’s HYP-6589 Receives NMPA Approval for Solid Tumor Clinical Trial

Fineline Cube Nov 8, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Drug

Ascentage Pharma’s Lisaftoclax and AceLink Therapeutics’ AL01211 Receive FDA Designations

Fineline Cube Nov 8, 2024

The Center for Drug Evaluation (CDE) website has indicated that China-based Ascentage Pharma’s (HKG: 6855)...

Company Drug

AskBio’s AB-1003 Receives Rare Pediatric Disease and Orphan Drug Designations from FDA

Fineline Cube Nov 8, 2024

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned subsidiary of Bayer AG (ETR: BAYN), has announced...

Company Deals

Teva Pharmaceutical Expands Partnerships in China’s One Health Sector with New Agreements

Fineline Cube Nov 8, 2024

Israel based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced new partnerships with Chinese firms...

Company Deals

Bayer’s Leap Forward: Implementing Salesforce on Alibaba Cloud for Customer Engagement

Fineline Cube Nov 8, 2024

Bayer (ETR: BAYN) has announced that its China Prescription Medicines business has fully adopted the...

Posts pagination

1 … 206 207 208 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.